Answers are grounded in this paper and cite their sources.
Background: Signet-ring cell carcinoma of the colon (SRCC) is a rare and distinct form of colon cancer associated with a poor prognosis. Despite the rapid advancement of personalized cancer treatments, there is currently no recommended specific treatment for this histological subtype. Materials and Methods: In this literature review, we explored and described the features that distinguish SRCC from other forms of colorectal cancer, focusing on clinical presentation, preoperative workup, and treatment. Results: One of the aspects that makes SRCC unique is that it is detected more often in the ascending vs other parts of the colon, regardless of age and gender. As a result, patients, unfortunately, present with a more advanced stage than other locations upon the initial diagnosis.Imaging techniques and tumor markers alone often fall short of revealing the extent of a tumor, and curative surgery procedures are rare. Neoadjuvant therapy in SRCC is currently recommended only in the context of a clinical trial. Adjuvant chemotherapy, on the other hand, appears promising in improving survival, especially in the stage III subgroup. SRCC have a higher incidence of BRCA1 and BRAF gene mutations when compared to adenocarcinomas, alongside to an increase in microsatellite instability. These particularities suggest that a targeted therapeutic approach may sometimes be considered. Conclusion: Given its specific clinical characteristics and poor survival outcomes, SRCC should be considered a distinct colon cancer entity. Although its rarity makes prospective trials difficult, a timely diagnosis and a correct treatment decision-making algorithm is important.
No takes yet. Share an insight, caveat, or question.
Farcaș et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: